Biophan`s Biomedical Breakthroughs to Gain - 500 Beiträge pro Seite

[V51]

(BSNS WIRE) Biophan`s Biomedical Breakthroughs to Gain Exposure with European
Institutional Investors at BioScience Economy Confere
Biophan`s Biomedical Breakthroughs to Gain Exposure with European Institutional
nvestors at BioScience Economy Conference

Business Editors / Health/Medical Writers

ROCHESTER, N.Y.--(BUSINESS WIRE)--Oct. 18, 2005--


Company CEO to Provide Detailed Report on Biophan Solutions and
Strategic Goals at Leading European Investor Forums

Biophan Technologies, Inc. (OTCBB: BIPH; FWB: BTN), a developer of
next-generation medical technology, announced that CEO Michael Weiner
has been invited to present the Company`s advanced solutions, which
address a range of multi-billion-dollar biomedical markets, at a
leading European investor community conference, the annual Bioscience
Economy Conference to be held on October 19 in Lausanne and Geneva,
Switzerland, and on October 20 in Milan, Italy.
"Biophan has received strong support from investors throughout
Europe, and we recognize the importance of increasing visibility and
understanding of Biophan`s technology and business strategy among
institutional investors in these markets," said Mr. Weiner, who will
make the upcoming presentation. "The Bioscience Economy Conference in
Switzerland and Italy will provide an excellent opportunity to further
expand our Company`s already notable recognition among institutional
investors in Europe. These investors and other financial professionals
have shown keen interest in our Company, and have enthusiastically
supported our business potential as a leading provider of advanced
solutions for the global healthcare industry."
Biophan is a biomedical development leader with a strong
intellectual property portfolio of 156 U.S. patents, licenses, or
applications and 46 international applications. The Company is focused
on commercializing its technology via licensing agreements with large
manufacturers. The Company`s diverse range of advanced solutions
enable safer and/or more effective implanted medical devices and other
medical tools that may be used with Magnetic Resonance Imaging (MRI)
environments. Biophan recently launched an initiative to expand its
presence in cardiovascular devices, one of the fastest-growing
segments of the biomedical industry, with an expected value of nearly
$28 billion before the end of this decade.

About the Bioscience Economy Conference(TM)

Capitalife organizes the Bioscience Economy Conference(TM), a
yearly series of conferences in Italy and Switzerland committed to
bridge the industrial and financial communities and expand their
reciprocal knowledge. Capitalife provides a link and offers tailored
high quality services to the life sciences industry and institutional
investors; focuses on European markets such as Italy, Switzerland,
U.K., and France; and offers to institutional investors independent
analyses and due diligence. For more information, please visit
http://www.capitalife.com/bioscience_conference.html.

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to
make biomedical devices safe and image compatible with the magnetic
resonance imaging (MRI) environment. The Company develops technologies
that enable implanted medical systems such as pacemakers,
interventional surgical devices such as catheters and guidewires, and
devices such as stents to be safely and effectively imaged under MRI.
Biophan is developing these same technologies to provide new MRI
contrast agents. Other applications include drug delivery and power
systems derived from body heat. Four Biophan technologies include
advances in nanotechnology and thin film coatings. Committed to growth
through innovation and developmental leadership, Biophan and its
licensors now hold a total of 156 U.S. patents, licenses, or
applications. This total includes 42 issued U.S. patents, 8
recently-allowed applications that will issue as patents in the near
future, and 106 pending applications at various stages of examination
at the U.S. Patent and Trademark Office, plus international
applications. The patents cover areas including nanotechnology
(nanomagnetic particle coatings), medical device designs, radio
frequency filters, polymer composites, thermoelectric materials for
batteries generating power from body heat, and photonics. Biophan has
joint development and licensing agreements with Boston Scientific and
NASA`s Ames Center for Nanotechnology. Biophan`s goal is to make all
biomedical devices capable of safely and successfully working with
MRI, and delivering other technologies which will improve quality of
life. Biophan is also listed on the Frankfurt Stock Exchange under the
ticker symbol "BTN." For more information, please visit
www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute
forward-looking statements within the meaning of applicable securities
laws. These statements reflect what Biophan anticipates, expects, or
believes may happen in the future. Biophan`s actual results could
differ materially from the outcome or circumstance expressed or
implied by such forward-looking statements as a result of a variety of
factors including, but not limited to: Biophan`s ability to develop
its technologies; the approval of Biophan`s patent applications; the
successful implementation of Biophan`s research and development
programs; the ability of Biophan to demonstrate the effectiveness of
its technology; the acceptance by the market of Biophan`s technology
and products incorporating such technology, the ability of Biophan to
effectively negotiate and enter into contracts with medical device
manufacturers for the licensing of Biophan`s technology; competition;
the ability of Biophan to raise capital to fund its operating and
research and development activities until it generates revenues
sufficient to do so; and the timing of projects and trends in future
operating performance, as well as other factors expressed from time to
time in Biophan`s periodic filings with the Securities and Exchange
Commission (the "SEC"). As a result, this press release should be read
in conjunction with Biophan`s periodic filings with the SEC which are
incorporated herein by reference. The forward-looking statements
contained herein are made only as of the date of this press release,
and Biophan undertakes no obligation to publicly update such
forward-looking statements to reflect subsequent events or
circumstances.



KEYWORD: EUROPE NORTH AMERICA NEW YORK UNITED STATES GERMANY
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY HOSPITALS MEDICAL DEVICES RADIOLOGY RESEA
CH & SCIENCE PROFESSIONAL SERVICES FINANCE TRADE SHOW
SOURCE: Biophan Technologies, Inc.


CONTACT INFORMATION:
Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
or
Press Interviews:
Jennifer Gould, 212-843-8037

*** end of story ***

[Ich_krieg_dich]

wer bist Du denn ?